177 related articles for article (PubMed ID: 38175441)
21. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.
Mejstrikova E; Volejnikova J; Fronkova E; Zdrahalova K; Kalina T; Sterba J; Jabali Y; Mihal V; Blazek B; Cerna Z; Prochazkova D; Hak J; Zemanova Z; Jarosova M; Oltova A; Sedlacek P; Schwarz J; Zuna J; Trka J; Stary J; Hrusak O
Haematologica; 2010 Jun; 95(6):928-35. PubMed ID: 20145275
[TBL] [Abstract][Full Text] [Related]
26. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
27. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
28. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract][Full Text] [Related]
29. Acute Myocardial Infarction during Induction Chemotherapy for Acute MLL t(4;11) Leukemia with Lineage Switch and Extreme Leukocytosis.
Colović N; Bogdanović A; Virijević M; Vidović A; Tomin D
Srp Arh Celok Lek; 2015; 143(11-12):734-8. PubMed ID: 26946771
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a
Brethon B; Lainey E; Caye-Eude A; Grain A; Fenneteau O; Yakouben K; Roupret-Serzec J; Le Mouel L; Cavé H; Baruchel A
Front Oncol; 2021; 11():637951. PubMed ID: 33718232
[TBL] [Abstract][Full Text] [Related]
31. Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
Permikin Z; Popov A; Verzhbitskaya T; Riger T; Plekhanova O; Makarova O; Froňková E; Trka J; Meyer C; Marschalek R; Tsaur G; Fechina L
Leuk Res; 2022 Jan; 112():106758. PubMed ID: 34864370
[No Abstract] [Full Text] [Related]
32. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
33. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
[TBL] [Abstract][Full Text] [Related]
34. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
35. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
36. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.
Coorens THH; Collord G; Treger TD; Adams S; Mitchell E; Newman B; Getz G; Godfrey AL; Bartram J; Behjati S
Nat Cancer; 2023 Aug; 4(8):1095-1101. PubMed ID: 37474833
[TBL] [Abstract][Full Text] [Related]
37. B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy.
Carulli G; Marini A; Ferreri MI; Azzarà A; Ottaviano V; Lari T; Rocco M; Giuntini S; Petrini M
Hematol Rep; 2012 Jul; 4(3):e15. PubMed ID: 23087804
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour E; Sasaki K; Short NJ; Ravandi F; Huang X; Khoury JD; Kanagal-Shamanna R; Jorgensen J; Khouri IF; Kebriaei P; Jain N; Alvarado Y; Kadia TM; Paul S; Garcia-Manero G; Dabaja BS; Burger JA; DiNardo CD; Daver NA; Montalban-Bravo G; Yilmaz M; Ohanian M; Ferrajoli A; Jacob J; Rostykus M; Garris R; O'Brien S; Kantarjian HM
Cancer; 2021 Jun; 127(12):2025-2038. PubMed ID: 33740268
[TBL] [Abstract][Full Text] [Related]
39. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
40. Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1;11)(p32;q23).
Yamamoto K; Yakushijin K; Mizutani Y; Okuni-Watanabe M; Goto H; Higashime A; Miyata Y; Kitao A; Matsumoto H; Saegusa J; Matsuoka H; Minami H
Cancer Genet; 2021 Jun; 254-255():92-97. PubMed ID: 33647817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
